Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Sep 13, 2023 4:10pm

113 Views

Post# 35634650

RE:RE:A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

My favorite parts were points 6 and 7 where Quento complained there weren't participants in any trial to show significance then completely contradicted himself and said there were! Haha.

And to your point Noteable, a healthcare investor just bought $15 mmillion worth of shares then bought AND exercised $2.25 millions worth of options.

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price